Citadel Advisors’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-178,337
| Closed | -$1.63M | – | 13927 |
|
|
2025
Q2 | $1.63M | Sell |
178,337
-871,285
| -83% | -$6.41M | ﹤0.01% | 6105 |
|
|
2025
Q1 | $8.34M | Buy |
1,049,622
+965,266
| +1,144% | +$7.07M | ﹤0.01% | 3098 |
|
|
2024
Q4 | $458K | Sell |
84,356
-525,146
| -86% | -$3.21M | ﹤0.01% | 8754 |
|
|
2024
Q3 | $4.4M | Buy |
609,502
+141,922
| +30% | +$1.3M | ﹤0.01% | 4157 |
|
|
2024
Q2 | $5.08M | Buy |
467,580
+307,032
| +191% | +$3.93M | ﹤0.01% | 3726 |
|
|
2024
Q1 | $3.01M | Sell |
160,548
-272,582
| -63% | -$6.29M | ﹤0.01% | 4788 |
|
|
2023
Q4 | $9.39M | Buy |
433,130
+52,862
| +14% | +$1.05M | ﹤0.01% | 2932 |
|
|
2023
Q3 | $7.83M | Buy |
380,268
+156,442
| +70% | +$4.52M | ﹤0.01% | 2994 |
|
|
2023
Q2 | $10.5M | Buy |
223,826
+168,302
| +303% | +$8.37M | ﹤0.01% | 2609 |
|
|
2023
Q1 | $2.33M | Buy |
55,524
+15,459
| +39% | +$665K | ﹤0.01% | 5067 |
|
|
2022
Q4 | $1.53M | Sell |
40,065
-123,031
| -75% | -$4.7M | ﹤0.01% | 5993 |
|
|
2022
Q3 | $6.39M | Buy |
163,096
+116,406
| +249% | +$4.5M | ﹤0.01% | 3467 |
|
|
2022
Q2 | $1.51M | Sell |
46,690
-59,256
| -56% | -$1.99M | ﹤0.01% | 6121 |
|
|
2022
Q1 | $3.51M | Sell |
105,946
-991,899
| -90% | -$37.3M | ﹤0.01% | 4868 |
|
|
2021
Q4 | $46.7M | Buy |
1,097,845
+427,855
| +64% | +$17.9M | 0.01% | 1220 |
|
|
2021
Q3 | $29.7M | Buy |
669,990
+24,180
| +4% | +$1.11M | 0.01% | 1577 |
|
|
2021
Q2 | $36.7M | Buy |
645,810
+614,791
| +1,982% | +$43.5M | 0.01% | 1408 |
|
|
2021
Q1 | $2.32M | Sell |
31,019
-468,425
| -94% | -$38.4M | ﹤0.01% | 6045 |
|
|
2020
Q4 | $43.2M | Sell |
499,444
-925,619
| -65% | -$68.2M | 0.01% | 1072 |
|
|
2020
Q3 | $87.1M | Sell |
1,425,063
-338,550
| -19% | -$17.2M | 0.02% | 537 |
|
|
2020
Q2 | $73.3M | Buy |
1,763,613
+1,155,806
| +190% | +$41.9M | 0.03% | 563 |
|
|
2020
Q1 | $17.5M | Buy |
607,807
+175,585
| +41% | +$10.2M | 0.01% | 1341 |
|
|
2019
Q4 | $31.2M | Buy |
432,222
+341,925
| +379% | +$42.1M | 0.01% | 1089 |
|
|
2019
Q3 | $12.7M | Buy |
90,297
+84,374
| +1,425% | +$14.1M | 0.01% | 1943 |
|
|
2019
Q2 | $1.08M | Sell |
5,923
-24,964
| -81% | -$4.26M | ﹤0.01% | 5571 |
|
|
2019
Q1 | $4.91M | Buy |
30,887
+570
| +2% | +$82.5K | ﹤0.01% | 3028 |
|
|
2018
Q4 | $2.9M | Sell |
30,317
-148,705
| -83% | -$17M | ﹤0.01% | 3568 |
|
|
2018
Q3 | $25.3M | Buy |
179,022
+153,861
| +612% | +$23.7M | 0.01% | 1213 |
|
|
2018
Q2 | $3.94M | Sell |
25,161
-51,785
| -67% | -$8.13M | ﹤0.01% | 3098 |
|
|
2018
Q1 | $12.4M | Buy |
76,946
+39,995
| +108% | +$6.79M | 0.01% | 1526 |
|
|
2017
Q4 | $6.09M | Sell |
36,951
-71,249
| -66% | -$6.91M | ﹤0.01% | 2245 |
|
|
2017
Q3 | $6.74M | Buy |
108,200
+93,289
| +626% | +$7.33M | 0.01% | 1975 |
|
|
2017
Q2 | $1.19M | Sell |
14,911
-90,621
| -86% | -$6.55M | ﹤0.01% | 3841 |
|
|
2017
Q1 | $7.5M | Buy |
105,532
+25,572
| +32% | +$1.5M | 0.01% | 1653 |
|
|
2016
Q4 | $4.08M | Sell |
79,960
-1,194,453
| -94% | -$56.3M | ﹤0.01% | 2197 |
|
|
2016
Q3 | $58.7M | Buy |
1,274,413
+624,405
| +96% | +$25.4M | 0.06% | 324 |
|
|
2016
Q2 | $19.6M | Buy |
650,008
+164,497
| +34% | +$5.49M | 0.02% | 799 |
|
|
2016
Q1 | $15.6M | Buy |
485,511
+245,838
| +103% | +$8.65M | 0.02% | 904 |
|
|
2015
Q4 | $14M | Buy |
239,673
+112,127
| +88% | +$5.55M | 0.02% | 1050 |
|
|
2015
Q3 | $5.4M | Buy |
+127,546
| New | +$7.86M | 0.01% | 1867 |
|
|
2015
Q2 | – | Sell |
-13,054
| Closed | -$839K | – | 9032 |
|
|
2015
Q1 | $656K | Sell |
13,054
-41,408
| -76% | -$1.78M | ﹤0.01% | 4518 |
|
|
2014
Q4 | $1.99M | Buy |
54,462
+13,425
| +33% | +$500K | ﹤0.01% | 2917 |
|
|
2014
Q3 | $1.29M | Buy |
+41,037
| New | +$1.19M | ﹤0.01% | 3393 |
|
Other funds holding SAGE
IA
HNB
Citadel Advisors's SAGE Position: Q3 2025 in Review
Citadel Advisors sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 178,337 shares — an estimated $1.63M sold.
Citadel Advisors first reported a position in SAGE in Q3 2014 and held it in 43 quarters. The position peaked at $87.1M in Q3 2020. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- Citadel Advisors reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- Citadel Advisors sold 178,337 Sage Therapeutics shares in Q3 2025, an estimated $1.63M.
- Citadel Advisors first reported a position in Sage Therapeutics in Q3 2014 and held it in 43 quarters.
- Citadel Advisors's Sage Therapeutics position peaked at $87.1M in Q3 2020.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.